LECT2–PHB2 Signaling: A New Target in Alcohol-Associated Hepatitis

Alcohol-associated hepatitis (AH) remains a high-mortality condition with limited effective therapies. A central driver of disease progression is excessive hepatic inflammation, particularly massive neutrophil infiltration, triggered by cytokine signaling, chemokine release (e.g., CXCL1, CXCL8), endothelial activation, and sterile inflammation mediated by damage-associated molecular patterns such as HMGB1 and mitochondrial DNA.

This article highlights a newly described LECT2–PHB2 molecular axis as a mechanistic contributor to inflammatory amplification in AH. Leukocyte cell–derived chemotaxin 2 (LECT2), a hepatokine previously implicated in metabolic and inflammatory liver diseases, appears to interact with prohibitin-2 (PHB2), a mitochondrial and signaling regulator protein. Emerging data suggest that dysregulation of this pathway exacerbates hepatocellular stress responses, enhances inflammatory signaling, and promotes neutrophil recruitment, thereby worsening liver injury.

Importantly, the LECT2–PHB2 interaction may represent a novel therapeutic opportunity. Targeting this axis could interrupt the self-sustaining loop of hepatocyte injury and immune activation that characterizes severe AH. Given the limited efficacy of current treatments—largely restricted to corticosteroids in selected patients—identifying pathways that modulate both hepatocellular stress and inflammatory amplification is clinically significant.

In summary, the LECT2–PHB2 axis provides fresh mechanistic insight into AH pathogenesis and may offer a promising target for future drug development aimed at reducing inflammation and improving outcomes in this devastating condition.